Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Combination of Gemcitabine, Oxaliplatin and Sorafenib (GEMOX-Sorafenib) in Patients With Advanced Biliary Tract Cancer

NCT00955721 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT00955721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00955721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Combination of Gemcitabine, Oxaliplatin and Sorafenib (GEMOX-Sorafenib) in Patients With Advanced Biliary Tract Cancer
Lead sponsor
University of Miami
Phase
Phase 1/2
Overall status
Terminated
Start date
August 31, 2009
Completion date
July 31, 2014
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, cholangiocarcinoma, gallbladder cancer